Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000488084 | SCV000575376 | uncertain significance | not provided | 2016-10-31 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000764471 | SCV000895538 | uncertain significance | Seckel syndrome 1; Familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000488084 | SCV001217035 | uncertain significance | not provided | 2022-09-06 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with alanine, which is neutral and non-polar, at codon 1616 of the ATR protein (p.Ser1616Ala). This variant is present in population databases (rs201492267, gnomAD 0.05%). This variant has not been reported in the literature in individuals affected with ATR-related conditions. ClinVar contains an entry for this variant (Variation ID: 425314). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The alanine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genome- |
RCV003126750 | SCV003801509 | uncertain significance | Seckel syndrome 1 | 2023-02-08 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003126751 | SCV003801510 | uncertain significance | Familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome | 2023-02-08 | criteria provided, single submitter | clinical testing |